Company Name/Ticker Underwriter Price Range
Shares
Advanced Accelerator Applications
AAAP
Citi
Jefferies & Co.
$13.00 - $15.00
5.4 mil
AltheaDx
IDGX
Citi
Jefferies & Co.
$12.00 - $14.00
4.6 mil
Asante Solutions
PUMP
Leerink Partners
Cowen & Company
$13.00 - $15.00
3.5 mil
Ascendis Pharma
ASND
BofA Merrill Lynch
Leerink Partners
$16.00 - $18.00
5.0 mil
Avinger
AVGR
Canaccord Genuity
Cowen & Company
$12.00 - $14.00
4.6 mil
Carbylan Therapeutics
CBYL
Leerink Partners
JMP Securities
$12.00 - $14.00
5.8 mil
Entellus Medical
ENTL
BofA Merrill Lynch
Piper Jaffray
$15.00 - $17.00
4.4 mil
Flex Pharma
FLKS
Jefferies & Co.
Piper Jaffray
$12.00 - $14.00
4.6 mil
Infraredx
REDX
RBC Capital Markets
Canaccord Genuity
$13.00 - $15.00
4.0 mil
InfraREIT
HIFR
BofA Merrill Lynch
Citi
$19.00 - $21.00
20.0 mil
Inotek Pharmaceuticals
ITEK
Cowen & Company
Piper Jaffray
$13.00 - $15.00
4.6 mil
Presbia
LENS
Jefferies & Co.
$11.00 - $13.00
4.2 mil
Shake Shack
SHAK
J.P. Morgan
Morgan Stanley
$14.00 - $16.00
5.0 mil
Spark Therapeutics
ONCE
J.P. Morgan
Credit Suisse
$15.00 - $17.00
5.5 mil
TRACON Pharmaceuticals
TCON
Wells Fargo Securities
Stifel
$12.00 - $14.00
3.6 mil
Zosano Pharma*
ZSAN
Ladenburg Thalmann & Co.
Roth Capital
$10.00 - $12.00
3.0 mil

Notes:
Zosano Pharma - *Previously filed to raise $70 million at a $139 million market cap in July 2014 but postponed its offering.
Please note our calendar only lists IPOs scheduled for the coming week. For a more in-depth calendar, please inquire about our institutional research service.
IPOs For Everyone Obtain Investor PacketAccess Your AccountInvest Online Today
Performance Disclosure: Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.

As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund’s average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees. An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.

Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds. The Renaissance IPO Index® (IPOUSA) is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The Renaissance International IPO Index® (IPOXUS) is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges. The S&P 500® Index (SPX) is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE.

Risk Disclosure: Investments in the Renaissance IPO ETF, symbol "IPO", the Renaissance International IPO ETF, symbol "IPOS" (the “ETFs”), and the Global IPO Fund, symbol "IPOSX" (the “Mutual Fund”) are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the “Funds”) invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.

Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit www.renaissancecapital.com. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.